R155
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.500
- PROTEIN_SECRETION+0.500
- MYC_TARGETS_V1+0.480
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.310
- MTORC1_SIGNALING+0.290
- ADIPOGENESIS+0.270
- PI3K_AKT_MTOR_SIGNALING+0.270
- ANDROGEN_RESPONSE+0.260
- UNFOLDED_PROTEIN_RESPONSE+0.260
- MYC_TARGETS_V2+0.250
Top 10 suppressed
- APICAL_SURFACE-0.410
- HEDGEHOG_SIGNALING-0.410
- MYOGENESIS-0.360
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.350
- KRAS_SIGNALING_DN-0.350
- APICAL_JUNCTION-0.290
- ESTROGEN_RESPONSE_EARLY-0.270
- ESTROGEN_RESPONSE_LATE-0.260
- WNT_BETA_CATENIN_SIGNALING-0.230
- ALLOGRAFT_REJECTION-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_KVAJYZ6F | Glial-neuronal tumor NOS | — | 0.844 |
| 2 | BS_CZ3NA7KV | Supratentorial Ependymoma | — | 0.833 |
| 3 | BS_74G5K7JF | Supratentorial Ependymoma | — | 0.795 |
| 4 | BS_C6ZZ3FY5 | Embryonal tumors | — | 0.789 |
| 5 | SJEPD031160_D1.RNA-Seq | EPN | EPN Tumor | 0.782 |
| 6 | BS_MT15SGJN | Supratentorial Ependymoma | — | 0.782 |
| 7 | BS_4NWHYH53 | Supratentorial Ependymoma | — | 0.775 |
| 8 | BS_CHDGRYHJ | Med | Medulloblastoma | 0.774 |
| 9 | MNG386 | — | — | 0.769 |
| 10 | R128 | — | — | 0.767 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.500 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.500 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.480 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.310 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.290 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.270 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.270 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.260 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.260 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.250 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.240 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.170 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.130 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.130 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.120 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.110 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.080 | Temsirolimus | — uncovered |
| GLYCOLYSIS | 0.070 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.050 | Remibrutinib | — uncovered |